BenchSci

BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence. For biomedical researchers and academics who are starting experiments, BenchSci offers a reagent intelligence platform that transforms published data into experiment-specific recommendations to reduce time, money and uncertainty in planning materials and methods. Unlike PubMed, Google Scholar, reagent directories, and vendors, BenchSci uses machine learning to decode open- and closed-access data, pre-print data, and data from third-party databases to present published figures with actionable insights. Backed by top-tier investors including Inovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci's platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We’re a remote-first Deloitte Tech Fast 50 and CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor. Learn more at www.benchsci.com.